Drug Trial Radar · NCT05800249
PE0116 Injection in Treatment of Patients With Advanced Solid Tumours
Last checked: Nov 19, 2026Latest source record: Dec 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Mar 8, 2021
Primary completion
Jun 2, 2023
Study completion Jun 16, 2023
Sponsor
- Lead sponsor
- Shanghai HyaMab Biotech Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients with Advanced Solid Tumor.
Conditions
- Locally Advanced/Metastatic Solid Tumors
Interventions
PE0116Drug
This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients with Advanced Solid Tumor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Drug Limited Toxicities (DLTs)Time frame: From Time of First dose through DLT observation period, 28 days
- Incidence of Treatment-emergent adverse event (TEAEs) and serious adverse events (SAEs).Time frame: From the start of treatment until up to 90 days after the last dose of study drug
- Number of patients with changes in laboratory parameters from baselineTime frame: From the start of treatment until up to 30(±7) days after the last dose of study drug
Locations
1 site in 1 country. Site status is shown where the registry gives one.
复旦大学附属中山医院
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.